Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of BRG01 for relapsed/metastatic nasopharyngeal cancer (NPC) treatment

Next Previous
Trial Profile

A phase I/II trial of BRG01 for relapsed/metastatic nasopharyngeal cancer (NPC) treatment

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BRG 01 (Primary)
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors BioSyngen

Most Recent Events

  • 18 Sep 2024 According to a BioSyngen media release, patient enrollment now underway for Phase II.
  • 18 Sep 2024 According to a BioSyngen media release, phase 1 data from this study presented at the 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain.
  • 13 Aug 2024 According to a BioSyngen media release, the U.S. Food and Drug Administration (FDA) has approved its BRG01 to proceed with a pivotal Phase II clinical trial.This marks the first cell therapy to enter Phase lI trials in both the U.S. and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma, demonstrating a breakthrough in solid tumor treatment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top